2013 Fiscal Year Final Research Report
Developmental reserch of the novel therapy for intractable pulmonary diseases such as pulmonary fibrosis
| Project/Area Number |
23591167
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | バイオマーカー / サイトカイン / 酸化ストレス |
|---|
| Research Abstract |
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. We demonstrated that patients with MPM had significantly higher serum levels of some markers such as HMGB1, thioredoxin, angiopoietin-1 than the population who had been exposed to asbestos but had not developed MPM. The difference in overall survival between groups with serum HMGB1 and angiopoietin-1 levels that were lower and higher than assumed cut-off values was significant.
Our data suggest that serum HMGB1, thioredoxin and angiopoietin-1 concentrations are useful clinical markers for MPM.
|
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Heme oxygenase-1 promoter polymorphism is associated with risk of malignant mesothelioma2012
Author(s)
Murakami A, Fujimori Y, Yoshikawa Y, Yamada S, Tamura K, Hirayama N, Terada T, Kuribayashi K, Tabata C, Fukuoka K, Tamaoki T, Nakano T.
-
Journal Title
Lung.
Volume: 190
Pages: 333-7
DOI
Peer Reviewed
-
-
